BeiGene
BGNE
#881
Rank
HK$172.87 B
Marketcap
HK$1,575
Share price
1.71%
Change (1 day)
4.40%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total assets

Total assets on the balance sheet as of June 2024 : HK$44.52 B

According to BeiGene 's latest financial reports the company's total assets are HK$44.52 B. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

BeiGene - Total assets on balance sheet (from 2014 to 2024)

Total assets by year

Year Total assets Change
2023-12-31HK$45.33 B-9.04%
2022-12-31HK$49.84 B-25.11%
2021-12-31HK$66.55 B53.26%
2020-12-31HK$43.42 B245.81%
2019-12-31HK$12.55 B-28.72%
2018-12-31HK$17.61 B115.46%
2017-12-31HK$8.17 B159.81%
2016-12-31HK$3.14 B247.73%
2015-12-31HK$0.90 B117.53%
2014-12-31HK$0.41 B354.72%
2013-12-31HK$91.48 M

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
HK$0.14 B-99.68%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$15.43 B-65.34%๐Ÿ‡บ๐Ÿ‡ธ USA